logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Flurbiprofen CAS 5104-49-4

Flurbiprofen CAS 5104-49-4

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 5104-49-4

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
5104-49-4
Appearance::
White To Off-white Crystalline Solid
Molecular Formula::
C15H13FO2
Molecular Weight::
244.26100
EINECS NO::
225-827-6
MDL NO::
MDL NO: MFCD00079303
CAS NO::
5104-49-4
Appearance::
White To Off-white Crystalline Solid
Molecular Formula::
C15H13FO2
Molecular Weight::
244.26100
EINECS NO::
225-827-6
MDL NO::
MDL NO: MFCD00079303
Flurbiprofen CAS 5104-49-4

Product Description:

Product Name: flurbiprofen CAS NO: 5104-49-4

 

 

Synonyms:

2-(2-fluoro-4-biphenylyl)propionicacid;

2-fluoro-alpha-methyl-4-biphenylaceticacid;

2-(2-Fluorobiphenyl-4-yl)propionic Acid;

 

 

Chemical & Physical Properties:

Appearance: White to off-white crystalline solid

Assay :≥98%

Density: 1.279 g/cm3 (25℃)

Boiling Point: 376℃

Melting Point: 110-112℃(lit.)

Stability: Stable at normal temperatures and pressures

Storage Condition: Keep tightly closed

Water Solubility: 8mg/L(room temperature)

Solubility: Methanol: soluble50mg/mL

 

 

Safety Information:

Signal Word: Danger

Symbol: GHS06

Safety Statements: S36/37/39-45

Hazard Class: 6.1(b)

Hazard Codes: T; C

HS Code: 2916399090

Packing Group: III

WGK Germany: 3

RTECS: DU8341000

RIDADR: UN 2811 6.1/PG 2

Risk Statement: R25

Hazard Declaration: H301

Caution Statements: P301 + P310

 

 

Flurbiprofen synthesis was originally reported in 1974. During a study of the pharmacological properties of a large number of substituted phenylalkanoic acids, including ibuprofen and ibufenac, the most potent were found to be substituted 2-(4-biphenyl)propionic acids. Further toxicological and pharmacological studies indicated that flurbiprofen possessed the most favorable therapeutic profile, so it was selected for further clinical development. It was not marketed until 1987, when it was introduced as the sodium salt as Ocufen, the first topical NSAID indicated for ophthalmic use in the United States. The indication for Ocufen is the same as that for Profenal—that is, to inhibit intraoperative miosis induced by prostaglandins in cataract surgery.

 

 

2-(2-fluoro-4-biphenylyl)propionicacid is anti-inflammatory drug for chronic arthritis and pain, inflammation of Deformation joint disease, and pain after surgery and tooth extraction. Mouse oral LD50 of 140mg/kg, rats 640-800mg/kg.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.